Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Stem Cell Res Ther ; 14(1): 108, 2023 04 27.
Article in English | MEDLINE | ID: mdl-37106393

ABSTRACT

BACKGROUND: Duchenne muscular dystrophy (DMD) is an incurable genetic disease characterized by degeneration and necrosis of myofibers, chronic inflammation, and progressive muscle weakness resulting in premature mortality. Immunosuppressive multipotent mesenchymal stromal cell (MSC) therapy could be an option for DMD patients. We focused on amnion-derived mesenchymal stromal cells (AMSCs), a clinically viable cell source owing to their unique characteristics, such as non-invasive isolation, mitotic stability, ethical acceptability, and minimal risk of immune reaction and cancer. We aimed to identify novel immunomodulatory effects of AMSCs on macrophage polarization and their transplantation strategies for the functional recovery of skeletal and cardiac muscles. METHODS: We used flow cytometry to analyze the expression of anti-inflammatory M2 macrophage markers on peripheral blood mononuclear cells (PBMCs) co-cultured with human AMSCs (hAMSCs). hAMSCs were intravenously injected into DMD model mice (mdx mice) to assess the safety and efficacy of therapeutic interventions. hAMSC-treated and untreated mdx mice were monitored using blood tests, histological examinations, spontaneous wheel-running activities, grip strength, and echocardiography. RESULTS: hAMSCs induced M2 macrophage polarization in PBMCs via prostaglandin E2 production. After repeated systemic hAMSC injections, mdx mice exhibited a transient downregulation of serum creatin kinase. Limited mononuclear cell infiltration and a decreased number of centrally nucleated fibers were indicative of regenerated myofibers following degeneration, suggesting an improved histological appearance of the skeletal muscle of hAMSC-treated mdx mice. Upregulated M2 macrophages and altered cytokine/chemokine expressions were observed in the muscles of hAMSC-treated mdx mice. During long-term experiments, a significant decrease in the grip strength in control mdx mice significantly improved in the hAMSC-treated mdx mice. hAMSC-treated mdx mice maintained running activity and enhanced daily running distance. Notably, the treated mice could run longer distances per minute, indicating high running endurance. Left ventricular function in DMD mice improved in hAMSC-treated mdx mice. CONCLUSIONS: Early systemic hAMSC administration in mdx mice ameliorated progressive phenotypes, including pathological inflammation and motor dysfunction, resulting in the long-term improvement of skeletal and cardiac muscle function. The therapeutic effects might be associated with the immunosuppressive properties of hAMSCs via M2 macrophage polarization. This treatment strategy could provide therapeutic benefits to DMD patients.


Subject(s)
Mesenchymal Stem Cells , Muscular Dystrophy, Duchenne , Humans , Animals , Mice , Muscular Dystrophy, Duchenne/genetics , Muscular Dystrophy, Duchenne/therapy , Mice, Inbred mdx , Amnion/metabolism , Leukocytes, Mononuclear/metabolism , Muscle, Skeletal/metabolism , Inflammation/pathology , Mesenchymal Stem Cells/metabolism , Disease Models, Animal
2.
Sci Rep ; 11(1): 2406, 2021 01 28.
Article in English | MEDLINE | ID: mdl-33510297

ABSTRACT

Acute graft-versus-host disease (GVHD) is characterized by severe tissue damage that is a life-threatening complication of allogeneic hematopoietic stem cell transplantation. Due to their immunosuppressive properties, mesenchymal stem cells (MSC) have been increasingly examined for the treatment of immune-related diseases. We aimed to assess the immunosuppressive effects of human amnion-derived MSC (AMSC) in a xenogeneic GVHD NOD/Shi-scid IL2rγnull mouse model using human peripheral blood mononuclear cells (PBMC). Additionally, we used human bone marrow-derived MSC (BMSC) as comparative controls to determine differences in immunomodulatory functions depending on the MSC origin. Administration of AMSC significantly prolonged survival, and reduced human tumor necrosis factor-α (TNF-α) concentration and percentage of programmed cell death protein-1 receptor (PD-1)+CD8+ T cell populations compared with in GVHD control mice. Furthermore, colonic inflammation score and percentage of human CD8+ T cell populations in AMSC-treated mice were significantly lower than in GVHD control and BMSC-treated mice. Interestingly, gene expression and protein secretion of the PD-1 ligands were higher in AMSC than in BMSC. These findings are the first to demonstrate that AMSC exhibit marked immunosuppression and delay acute GVHD progression by preventing T cell activation and proliferation via the PD-1 pathway.


Subject(s)
Amnion/cytology , Graft vs Host Disease/prevention & control , Lymphocyte Activation/immunology , Mesenchymal Stem Cells/cytology , Mesenchymal Stem Cells/metabolism , T-Lymphocytes/immunology , T-Lymphocytes/metabolism , Animals , B7-H1 Antigen/genetics , B7-H1 Antigen/metabolism , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/metabolism , Cytokines/metabolism , Disease Models, Animal , Disease Progression , Graft vs Host Disease/etiology , Graft vs Host Disease/pathology , Heterografts , Humans , Immunohistochemistry , Mesenchymal Stem Cell Transplantation/methods , Mice , Programmed Cell Death 1 Ligand 2 Protein/genetics , Programmed Cell Death 1 Ligand 2 Protein/metabolism , Treatment Outcome
3.
J Biosci Bioeng ; 101(5): 421-6, 2006 May.
Article in English | MEDLINE | ID: mdl-16781472

ABSTRACT

Qbeta replicase, an RNA-dependent RNA polymerase of RNA coliphage Qbeta, is a heterotetramer composed of a phage-encoded beta-subunit and three host-encoded proteins: the ribosomal protein S1 (alpha-subunit), EF-Tu, and EF-Ts. Several purification methods for Qbeta replicase were described previously. However, in our efforts to improve the production of Qbeta replicase, a substantial amount of the beta-subunit overproduced in Escherichia coli cells was found as insoluble aggregates. In this paper, we describe two kinds of method of producing Qbeta replicase. In one kind, both EF-Tu and EF-Ts subunits were expressed with the beta-subunit, and in the other kind, the beta-subunit was genetically fused with EF-Tu and EF-Ts. The fused protein, a single-chain alpha-less Qbeta replicase, was mostly found in the soluble fraction and could be readily purified. These results pave the way for the large-scale production of the highly purified form of this enzyme.


Subject(s)
Escherichia coli/genetics , Escherichia coli/metabolism , Protein Engineering/methods , Q beta Replicase/biosynthesis , Q beta Replicase/chemistry , Enzyme Activation , Genetic Enhancement , Protein Subunits , Q beta Replicase/genetics , Q beta Replicase/isolation & purification , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/isolation & purification , Recombinant Fusion Proteins/metabolism
4.
J Biosci Bioeng ; 93(3): 322-7, 2002.
Article in English | MEDLINE | ID: mdl-16233208

ABSTRACT

The kinetic properties of Qbeta replicase, an RNA-dependent RNA polymerase, were investigated experimentally. The reaction at the A-incorporation site was inhibited by UTP and CTP with inhibition constants of 3.2 and 2.7 mM, respectively, while the reactions at the U-, G-, and C-incorporation sites were inhibited by ATP with inhibition constants of 1.09, 1.25, and 1.48 mM, respectively. When nucleotide concentrations were low, C was incorporated at the fastest rate and G at the slowest. Accordingly, the G-incorporation step largely limits the overall reaction rate. From the obtained kinetic parameters, calculations showed that the optimum ratio of the concentrations of the four nucleotides could be achieved by increasing the ratio of GTP concentration with a concomitant decrease in the ratios of CTP and ATP concentrations. Consequently, a 60 to 140% increase in the reaction rate is expected as compared to the rate with equimolar ratio of the four nucleotides.

SELECTION OF CITATIONS
SEARCH DETAIL
...